Gilla Kaplan

Executive

Avalo Therapeutics, Inc.Tyra Biosciences, Inc.

Insider activity · 24 months0 buys2 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 2 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (2 ops.)

€267k

Latest filing published 31 Mar 2026 for Avalo Therapeutics, Inc.. Read the official filing

Filing timeline

BuySale

Gilla Kaplan

Insider track record

Disclosed buys

Disclosed sells

Signal history

Gilla Kaplan: trading record in brief

This profile gathers the share dealings of Gilla Kaplan across 2 companies, led by Tyra Biosciences, Inc. and Avalo Therapeutics, Inc. Between 13 June 2024 and 28 March 2026, the trades on record add up to 6 filings.

No open-market purchase appears, only 2 sales worth €267k. Besides market trades, the filings include 4 option exercises.

The record was last updated on 31 March 2026 with an option exercise in Avalo Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.